ClinicalTrials.gov record
Completed Phase 1 Interventional

A Study of Crenezumab in Participants With Mild to Moderate Alzheimer Disease

ClinicalTrials.gov ID: NCT02353598

Public ClinicalTrials.gov record NCT02353598. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 4, 2026, 12:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase Ib, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Arm, Multiple-Dose Study to Assess The Safety, Tolerability, And Pharmacokinetics of Intravenous Crenezumab Administered in Patients With Mild to Moderate Alzheimer's Disease

Study identification

NCT ID
NCT02353598
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1
Lead sponsor
Genentech, Inc.
Industry
Enrollment
77 participants

Conditions and interventions

Interventions

  • Crenezumab dose level 1 Drug
  • Crenezumab dose level 2 Drug
  • Crenezumb dose level 3 Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
50 Years to 90 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 25, 2015
Primary completion
Nov 29, 2016
Completion
Mar 25, 2019
Last update posted
Jul 23, 2019

2015 – 2019

United States locations

U.S. sites
13
U.S. states
9
U.S. cities
13
Facility City State ZIP Site status
Mayo Clinic Scottsdale Phoenix Arizona 85054
UCSF - Memory and Aging Center San Francisco California 94158
Brain Matters Research, Inc. Delray Beach Florida 33445
Miami Jewish Health Systems Miami Florida 33137
Bioclinica Orlando Orlando Florida 32806
Bioclinica The Villages The Villages Florida 32162
Indiana University School Of Medicine; Department Of Neurology Indianapolis Indiana 46202
Hattiesburg Clinic Hattiesburg Mississippi 39401
Millennium Psychiatric Associates, LLC St Louis Missouri 63132
Columbia University Medical Center New York New York 10032
UNiversity of Rochester Rochester New York 14620
Rhode Island Mood & Memory Research Institute East Providence Rhode Island 02914
Roper St. Francis Healthcare; Clinical Biotechnology Research Institute Charleston South Carolina 29401

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02353598, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 23, 2019 · Synced May 4, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02353598 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →